Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + vandetanib
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of everolimus, an mTOR inhibitor, and vandetanib, a multi-kinase inhibitor targeting RET, VEGFR, and EGFR. This combination has shown activity in pediatric and young adult patients with advanced cancers, with potential to overcome resistance to either drug used alone.
02
Targets
ABCG2 (Breast cancer resistance protein)VEGFR2 (Vascular endothelial growth factor receptor 2)Mechanistic target of rapamycin complex 1EGFR T790M (Epidermal growth factor receptor T790M mutant)RET (Rearranged during transfection receptor tyrosine kinase)ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on everolimus + vandetanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + vandetanib.